vs
Esperion Therapeutics, Inc.（ESPR）与PERDOCEO EDUCATION Corp（PRDO）财务数据对比。点击上方公司名可切换其他公司
PERDOCEO EDUCATION Corp的季度营收约是Esperion Therapeutics, Inc.的1.3倍（$211.6M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 20.0%），过去两年PERDOCEO EDUCATION Corp的营收复合增速更高（12.2% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Perdoceo Education是美国上市营利性教育集团，前身为职业教育公司（Career Education Corporation），旗下运营五所美国营利性大学，包括美国洲际大学、科罗拉多理工大学、南加利福尼亚大学、三叉戟国际大学及圣奥古斯丁健康科学大学，业务覆盖高等教育、职业教育及健康科学相关教育领域。
ESPR vs PRDO — 直观对比
营收规模更大
PRDO
是对方的1.3倍
$168.4M
营收增速更快
ESPR
高出123.8%
20.0%
两年增速更快
PRDO
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $211.6M |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | 19.8% |
| 净利率 | — | — |
| 营收同比 | 143.7% | 20.0% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.32 | $0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRPRDO
| Q4 25 | $168.4M | $211.6M | ||
| Q3 25 | $87.3M | $211.9M | ||
| Q2 25 | $82.4M | $209.6M | ||
| Q1 25 | $65.0M | $213.0M | ||
| Q4 24 | $69.1M | $176.4M | ||
| Q3 24 | $51.6M | $169.8M | ||
| Q2 24 | $73.8M | $166.7M | ||
| Q1 24 | $137.7M | $168.3M |
净利润ESPRPRDO
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $39.9M | ||
| Q2 25 | $-12.7M | $41.0M | ||
| Q1 25 | $-40.5M | $43.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $38.3M | ||
| Q2 24 | $-61.9M | $38.4M | ||
| Q1 24 | $61.0M | $39.4M |
营业利润率ESPRPRDO
| Q4 25 | 50.6% | 19.8% | ||
| Q3 25 | -11.4% | 24.1% | ||
| Q2 25 | 8.6% | 24.5% | ||
| Q1 25 | -34.0% | 24.3% | ||
| Q4 24 | -6.4% | 21.1% | ||
| Q3 24 | -31.0% | 26.4% | ||
| Q2 24 | 3.5% | 27.6% | ||
| Q1 24 | 52.5% | 27.5% |
净利率ESPRPRDO
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | 18.8% | ||
| Q2 25 | -15.4% | 19.6% | ||
| Q1 25 | -62.2% | 20.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | 22.5% | ||
| Q2 24 | -83.9% | 23.0% | ||
| Q1 24 | 44.3% | 23.4% |
每股收益（稀释后）ESPRPRDO
| Q4 25 | $0.32 | $0.55 | ||
| Q3 25 | $-0.16 | $0.60 | ||
| Q2 25 | $-0.06 | $0.62 | ||
| Q1 25 | $-0.21 | $0.65 | ||
| Q4 24 | $-0.14 | $0.46 | ||
| Q3 24 | $-0.15 | $0.57 | ||
| Q2 24 | $-0.33 | $0.57 | ||
| Q1 24 | $0.34 | $0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $111.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $972.4M |
| 总资产 | $465.9M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRPRDO
| Q4 25 | $167.9M | $111.0M | ||
| Q3 25 | $92.4M | $159.5M | ||
| Q2 25 | $86.1M | $172.1M | ||
| Q1 25 | $114.6M | $132.1M | ||
| Q4 24 | $144.8M | $109.1M | ||
| Q3 24 | $144.7M | $238.0M | ||
| Q2 24 | $189.3M | $127.9M | ||
| Q1 24 | $226.6M | $125.8M |
股东权益ESPRPRDO
| Q4 25 | $-302.0M | $972.4M | ||
| Q3 25 | $-451.4M | $997.9M | ||
| Q2 25 | $-433.5M | $984.6M | ||
| Q1 25 | $-426.2M | $970.3M | ||
| Q4 24 | $-388.7M | $959.5M | ||
| Q3 24 | $-370.2M | $935.4M | ||
| Q2 24 | $-344.2M | $899.5M | ||
| Q1 24 | $-294.3M | $866.1M |
总资产ESPRPRDO
| Q4 25 | $465.9M | $1.2B | ||
| Q3 25 | $364.0M | $1.3B | ||
| Q2 25 | $347.1M | $1.3B | ||
| Q1 25 | $324.0M | $1.3B | ||
| Q4 24 | $343.8M | $1.2B | ||
| Q3 24 | $314.1M | $1.1B | ||
| Q2 24 | $352.3M | $1.1B | ||
| Q1 24 | $373.1M | $1.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $40.1M |
| 自由现金流经营现金流 - 资本支出 | — | $37.9M |
| 自由现金流率自由现金流/营收 | — | 17.9% |
| 资本支出强度资本支出/营收 | 0.0% | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $216.7M |
8季度趋势，按日历期对齐
经营现金流ESPRPRDO
| Q4 25 | $45.2M | $40.1M | ||
| Q3 25 | $-4.3M | $41.2M | ||
| Q2 25 | $-31.4M | $78.8M | ||
| Q1 25 | $-22.6M | $65.1M | ||
| Q4 24 | $-35.0M | $17.6M | ||
| Q3 24 | $-35.3M | $51.0M | ||
| Q2 24 | $-7.2M | $38.5M | ||
| Q1 24 | $53.8M | $54.5M |
自由现金流ESPRPRDO
| Q4 25 | — | $37.9M | ||
| Q3 25 | — | $39.4M | ||
| Q2 25 | — | $76.0M | ||
| Q1 25 | — | $63.4M | ||
| Q4 24 | — | $16.0M | ||
| Q3 24 | $-35.5M | $50.0M | ||
| Q2 24 | $-7.3M | $37.7M | ||
| Q1 24 | $53.8M | $53.3M |
自由现金流率ESPRPRDO
| Q4 25 | — | 17.9% | ||
| Q3 25 | — | 18.6% | ||
| Q2 25 | — | 36.3% | ||
| Q1 25 | — | 29.8% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | -68.7% | 29.4% | ||
| Q2 24 | -9.9% | 22.6% | ||
| Q1 24 | 39.0% | 31.7% |
资本支出强度ESPRPRDO
| Q4 25 | 0.0% | 1.1% | ||
| Q3 25 | 0.0% | 0.9% | ||
| Q2 25 | 0.0% | 1.3% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.0% | 0.9% | ||
| Q3 24 | 0.3% | 0.6% | ||
| Q2 24 | 0.1% | 0.5% | ||
| Q1 24 | 0.1% | 0.7% |
现金转化率ESPRPRDO
| Q4 25 | — | — | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.33× | ||
| Q2 24 | — | 1.00× | ||
| Q1 24 | 0.88× | 1.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PRDO
| CTU | $107.0M | 51% |
| AIUS | $60.8M | 29% |
| University Of St Augustine For Health Sciences Llc | $43.7M | 21% |
| Other | $1.1M | 1% |
